A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

(Reuters) -UnitedHealth CEO Andrew Witty said on Thursday that healthcare in the U.S. needs to be "less confusing, less ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST. GSK said in a statement that it had agreed ...

The new facility at Stainton, near Barnard Castle, will power the nearby Glaxo Smith Kline factory for 40 years. The pharmaceutical and biotechnology company said the solar farm will help maintain the ...